Masked Selection: A Straightforward and Flexible Approach for the Selection of Binders Against Specific Epitopes and Differentially Expressed Proteins by Phage Display
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Masked Selection: A Straightforward and Flexible Approach for the Selection of Binders Against Specific Epitopes and Differentially Expressed Proteins by Phage Display
Authors
Keywords
-
Journal
MOLECULAR & CELLULAR PROTEOMICS
Volume 13, Issue 2, Pages 653-665
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2013-12-21
DOI
10.1074/mcp.o112.025486
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models
- (2013) D. Siolas et al. CANCER RESEARCH
- Epithelial cell adhesion molecule-targeted drug delivery for cancer therapy
- (2013) Manuel Simon et al. Expert Opinion on Drug Delivery
- Single-Domain Antibody-Based and Linker-Free Bispecific Antibodies Targeting Fc RIII Induce Potent Antitumor Activity without Recruiting Regulatory T Cells
- (2013) C. Rozan et al. MOLECULAR CANCER THERAPEUTICS
- Single-domain antibodies: a versatile and rich source of binders for breast cancer diagnostic approaches
- (2012) Klervi Even-Desrumeaux et al. Molecular BioSystems
- Multiple Functions of Sushi Domain Containing 2 (SUSD2) in Breast Tumorigenesis
- (2012) A. P. Watson et al. MOLECULAR CANCER RESEARCH
- Molecular Characterisation of Endogenous Vangl2/Vangl1 Heteromeric Protein Complexes
- (2012) Edwige Belotti et al. PLoS One
- Single-domain antibodies that compete with the natural ligand fibroblast growth factor block the internalization of the fibroblast growth factor receptor 1
- (2011) Gianluca Veggiani et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Up-regulation of METCAM/MUC18 promotes motility, invasion, and tumorigenesis of human breast cancer cells
- (2011) Guo-fang Zeng et al. BMC CANCER
- Expression of Id-1 Is Regulated by MCAM/MUC18: A Missing Link in Melanoma Progression
- (2011) M. Zigler et al. CANCER RESEARCH
- Src Regulates Tyr20Phosphorylation of Transferrin Receptor-1 and Potentiates Breast Cancer Cell Survival
- (2011) Jinlong Jian et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- DARPins Recognizing the Tumor-Associated Antigen EpCAM Selected by Phage and Ribosome Display and Engineered for Multivalency
- (2011) Nikolas Stefan et al. JOURNAL OF MOLECULAR BIOLOGY
- Strong and oriented immobilization of single domain antibodies from crude bacterial lysates for high-throughput compatible cost-effective antibody array generation
- (2010) Klervi Even-Desrumeaux et al. Molecular BioSystems
- Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists
- (2010) B. Wu et al. SCIENCE
- Identification of MCAM/CD146 as the Target Antigen of a Human Monoclonal Antibody that Recognizes Both Epithelioid and Sarcomatoid Types of Mesothelioma
- (2009) Scott Bidlingmaier et al. CANCER RESEARCH
- Engineered protein scaffolds as next-generation antibody therapeutics
- (2009) Michaela Gebauer et al. CURRENT OPINION IN CHEMICAL BIOLOGY
- Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen
- (2009) Ghislaine Behar et al. FEBS Journal
- Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer
- (2008) M. Schmidt et al. CLINICAL CANCER RESEARCH
- Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells
- (2007) Amara C. Siva et al. JOURNAL OF IMMUNOLOGICAL METHODS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now